NCT00473577View on ClinicalTrials.gov

Study of the Tolerability, Safety, and Pharmacokinetics of CRA-024781 in Cancer Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

November 30, 2007

Study Completion Date

December 31, 2007

Conditions
Hematologic NeoplasmsNeoplasms
Interventions
DRUG

CRA-24781

Trial Locations (1)

60643

University of Chicago, Chicago

Sponsors

Lead Sponsor

Pharmacyclics LLC.
All Listed Sponsors
lead

Pharmacyclics LLC.

INDUSTRY